The Signal Report // SUPPLEMENTS
Supplements.
What the studies actually measured versus what the label claims, from a formulator who holds his own category to the bar. All reports →
44 in this beat · page 1 of 5
Is red yeast rice a statin?
Red yeast rice lowers LDL about as much as a low-dose statin, because its main monacolin is the same molecule as lovastatin. A test of 37 products found doses from 83% under the label to 266% over, citrinin in every one, and EFSA could not name a safe intake.
Read the report → Report 254 · Supplements · 2026-11-18 · 7 minDoes ginkgo prevent memory loss?
Two large placebo-controlled trials gave a standardized ginkgo extract to nearly 6,000 older adults for five to six years. Neither reduced dementia, and GEM found no slowing of memory decline. What the trials measured, what they can't rule out, and the small, low-certainty signal a 2026 Cochrane review still sees in people who already have dementia.
Read the report → Report 248 · Supplements · 2026-11-15 · 8 minWhat the NOVOS Core vascular trial found
A November 2026 trial of NOVOS Core, a 12-ingredient longevity powder, reported better flow-mediated dilation, lower arterial stiffness and 6 mmHg lower systolic pressure than placebo after six months. It analyzed 43 of 61 people, measured stiffness with an arm-cuff algorithm, tested only surrogate markers, and was supplied and part-funded by the maker.
Read the report → Report 242 · Supplements · 2026-11-10 · 7 minWhat the PQQ brain-supplement trial found
A November 2026 trial gave healthy postmenopausal women a daily capsule of PQQ, GABA, 100 mg caffeine and B vitamins, and reported a 5.89-point gain on a global cognition index over placebo. It tested a blend, eleven sub-scores went uncorrected (one went the wrong way), and the registry names the manufacturer as sponsor.
Read the report → Report 236 · Supplements · 2026-11-07 · 7 minDoes high-dose DHA protect your memory?
A two-year USC trial gave 365 at-risk older adults 2,000 mg of DHA a day. Spinal-fluid DHA rose, which answers the dose question. Memory scores and hippocampal volume matched placebo. What the trial settles, the press-release stretch, and what it leaves open.
Read the report → Report 230 · Supplements · 2026-11-04 · 7 minDoes microdosing psilocybin work?
Microdosers feel better. So do people taking empty capsules they think might be microdoses. What the placebo-controlled trials found, why participants kept guessing their dose, and the honest case that the question isn't closed.
Read the report → Report 224 · Supplements · 2026-11-01 · 7 minIs ashwagandha bad for your liver?
One case series found three deaths among eight patients. A trial of 1,002 people found no liver signal. They aren't contradicting each other: what each design can see, why nobody can give you a rate, and who should take the warning seriously.
Read the report → Report 218 · Supplements · 2026-10-29 · 7 minDoes vitamin D prevent fractures?
A 2026 BMJ review pooled 69 trials and 153,902 people. Vitamin D alone did nothing measurable for fractures or falls. Vitamin D plus calcium was statistically significant, about 1 fewer fracture per 100 people, and below the bar the authors set in advance. Most of that came from one 1992 nursing-home trial.
Read the report → Report 212 · Supplements · 2026-10-26 · 7 minWhat the lion's mane and reishi anxiety trial found
A pre-registered Northumbria trial gave 84 stressed young women lion's mane, a lion's mane and reishi blend, or placebo for 28 days. The blend beat lion's mane alone on the primary anxiety score, but not placebo, and with less lion's mane in it. Meanwhile anxiety fell by close to half across all three groups. What the trial shows, and the three questions to ask any product that cites it.
Read the report → Report 206 · Supplements · 2026-10-23 · 7 minWhat the vitamin C pre-leukemia trial found
"Vitamin C may benefit people with pre-cancer blood disorders" made the rounds in September. The EVITA trial behind it missed its primary endpoint; the survival result came from a post hoc analysis that wasn't in the protocol. What each result can say, why most deaths were infections, and the deficiency finding worth acting on.
Read the report →